Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Exclusion Criteria

• •Fasting LDL-C \>130 mg/dL (3.4 mmol/L) at screening
• •On an optimal dose of statin (investigator's discretion), unless statin intolerant, with or without other lipid-lowering therapy (e.g. ezetimibe)
• •Participants on lipid-lowering therapies (such as e.g. statins, ezetimibe) must be on a stable dose for ≥30 days before screening with no planned medication or dose changes during study participation
• •Participants on a documented regimen of LDL-apheresis for ≥ 3 months before screening will be allowed to continue the apheresis during the study, if needed. The apheresis schedule/settings/duration must be stable prior to screening, are not allowed to change during the double-blind period of the trial and must permit that an apheresis coincides with each study visit.
• •Documented evidence of a null (negative) mutation in both LDLR alleles
• •Previous treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9
• •History of poor response to therapy with any monoclonal antibody directed towards PCSK9 (e.g. \<15% reduction in LDL-C)
• •Treatment with mipomersen or lomitapide (within 5 months of screening)
• •Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
• •Heterozygous familial hypercholesterolemia (HeFH)
• •Body weight (at the screening and/or randomization (Day 1) visit) \<16 kg for participants 6 to \<12 years (at screening) or \<11 kg for participants 2 to \<6 years (at screening)
• •Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation \>3x ULN, or total bilirubin elevation \>2x ULN (except patients with Gilbert's syndrome)
• •Pregnant or nursing females
• •Recent and/or planned use of other investigational medicinal products or devices